Axogen, Inc. is a medical device company focused on the development and commercialization of technologies for peripheral nerve regeneration and repair. The company provides a portfolio of products for surgeons and healthcare providers to treat sensory, mixed, and motor peripheral nerve discontinuities. Key products include Avance, an acellular nerve allograft scaffold; Avance Nerve Graft, a processed human nerve allograft; Axoguard Nerve Connector, a porcine submucosa extracellular matrix coaptation aid; Axoguard Nerve Protector and Axoguard HA+ Nerve Protector, which wrap and protect damaged nerves; Axoguard Nerve Cap, used to reduce neuroma development; and Avive+ Soft Tissue Matrix, a multi-layer amniotic membrane allograft. These solutions are utilized in extremities, oral maxillofacial, head and neck, breast reconstruction, and urology applications. The company serves markets in the United States, Canada, Germany, the United Kingdom, Spain, and other countries. Axogen’s products are designed to address nerve injuries resulting from traumatic events or surgical procedures, aiming to restore nerve function and improve patient quality of life.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Medical Devices Homepage axogeninc.com
Sector Healthcare IR page ir.axogeninc.com
Tags
peripheral nerve repair, nerve grafts, regenerative medicine, tissue engineering, surgical implants, neuroma prevention, nerve connectors, soft tissue matrix, Avance, Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, Avive+ Soft Tissue Matrix
Press page ir.axogeninc.com/news-events/press-releases

Metrics

Valuation  
Market cap $ 2.504B
Market cap (USD) $ 2.504B
P/E -64.49
PEG —
P/BV 5.05
P/S 9.38
P/OCF 88.28
P/FCF 113.60
Dividend yield —
Turnover / mcap —
Returns  
ROE -13.5%
ROI -8.9%
ROIC -3.3%
Profit margin -7.0%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 37.6%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 28
Quality score -41.2%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2002 FY 2001 FY 2000
Revenue 225.208M 187.338M 159.012M 138.584M 127.358M 112.3M 106.712M 83.937M 60.426M 41.108M 27.331M 16.817M 10.947M 7.692M 4.849M 3.004M 24.911M — — — 15.929M 14.596M
Net profit -15.703M -9.964M -21.716M -28.948M -26.985M -23.786M -29.135M -22.397M -10.445M -14.411M -13.356M -17.71M -14.557M -9.418M -9.219M -5.423M 15.046M -1.041M -748.98K — 1.343M -2.859M
Free cash flow -2.933M 1.434M -19.588M -36.144M -41.216M -31.531M -24.536M -24.144M -10.343M -12.168M -13.461M -10.993M -10.624M -8.71M -7.1M — 15.44M -476.797K -466.947K — -3.295M -1.696M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2002 FY 2001 FY 2000
Share price 32.73 16.48 6.83 9.98 9.37 17.9 17.89 20.43 28.3 9 5 3.59 4.49 2.5 2.4 — — — — — — —
Price performance 12m 0.99 1.41 -0.32 0.07 -0.48 0 -0.12 -0.28 2.14 0.8 0.39 -0.2 0.8 0.04 — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 8.05M 11.1M 15.3M 16.9M 17.6M 18.2M 22.2M 25.1M 24.1M 26.2M
↳ YoY growth +68.4% +37.4% +38.5% +10.6% +4.0% +3.1% +22.2% +13.3% -4.1% +8.6%
↳ 5y CAGR +58.8% +60.2% +51.9% +42.6% +29.8% +17.7% +14.9% +10.4% +7.3% +8.2%
Borrowings, current (USD) 20,899 735,017 28,000 1.74M — — — — — —
Borrowings, non-current (USD) 20.3M 19.9M 35,000 1.6M 32M 44.8M 45.7M 46.6M 47.5M 48.4M
Lease liabilities (USD) — — — 3.33M 21.7M 22.6M 21.7M 22.7M 21.2M 19.2M
Cash and deposits (USD) 30M 36.5M 24.3M 35.7M 48.8M 32.8M 15.3M 31M 27.6M 35.5M
Intangible assets (USD) 828,979 936,992 1.18M 1.52M 2.05M 2.86M 3.65M 4.53M 5.58M 6.75M
Right-of-use assets (USD) — — — 3.13M 15.6M 15.2M 14.4M 15.6M 14.3M 12.7M
Net debt (borrowings + leases - cash) (USD) -9.73M -15.9M -24.2M -29.1M 5M 34.7M 52.1M 38.3M 41.1M 32.1M
Cash flow detail
Operating cash flow (USD) -11.2M -9.24M -17.9M -19.9M -9.63M -13.4M -16.1M -5.72M 4.54M 812,000
Purchases of property, plant and equipment (USD) -963,787 -1.11M -6.28M -4.66M -21.9M -27.8M -20.1M -13.9M -3.1M -3.75M
Purchases of intangible assets (USD) -225,768 -187,006 -321,000 -562,000 -692,000 -589,000 -1.18M -1.05M -1.42M -1.85M
Change in receivables (cash effect) (USD) -3.35M -3.24M -5.11M -2.14M -635,000 -499,000 -4.64M -2.69M 392,000 -2.46M
Change in inventories (cash effect) (USD) -1.52M -1.86M -6.01M -3.77M -910,000 -7.48M -3.66M -6.05M -10.2M -9.19M
Change in payables (cash effect) (USD) 3.44M 1.93M 3.71M 2.92M 4.96M -270,000 660,000 6.51M 125,000 -7.16M
Interest paid (cash effect) (USD) -5.77M -2.2M -1.33M -34,000 -822,000 -495,000 0.00 -1.94M -7.3M -6.81M
Share-based compensation (USD) 1.39M 3.61M 7.61M 10.3M 8.47M 10.9M 15.6M 14.4M 15.9M 30.1M
Operating cash flow before change in receivables (USD) -7.86M -6M -12.8M -17.7M -8.99M -12.9M -11.4M -3.03M 4.14M 3.28M
Free cash flow (OCF - PPE - intangibles) (USD) -12.4M -10.5M -24.5M -25.1M -32.2M -41.8M -37.3M -20.6M 11,000 -4.78M
Income detail
Research and development expense (USD) 4.21M 6.7M 11.8M 17.5M 17.8M 24.2M 27.2M 28.3M 27.8M 32.9M
↳ 5y CAGR +43.3% +36.2% +40.8% +42.0% +40.7% +41.8% +32.3% +19.2% +9.7% +13.0%
Provision for credit losses (USD) 79,593 223,323 852,000 514,000 -105,000 -41,000 612,000 -271,000 650,000 400,000
Credit cost ratio (credit losses / average receivables) (%) 1.2% 2.3% 6.5% 3.2% 0.6% 0.2% 3.0% 1.1% 2.6% 1.6%
Reported Mar 1, 2017 Feb 28, 2018 Feb 26, 2019 Feb 24, 2020 Mar 1, 2021 Feb 25, 2022 Mar 14, 2023 Mar 5, 2024 Feb 26, 2025 Feb 24, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Axogen, Inc. — Regulation FD Disclosure Bull 2 Bear 0 Product/operations

On November 9, 2026, Axogen, Inc. (the “Company”) posted a corporate presentation to its website at https://ir.axogeninc.com/news-events. The Company may use the corporate presentation from time to time in conversation with analysts, investors, and others. A copy of the presentation is furnished as Exhibit 99.1.

November 03, 2026 7:00am EST

ALACHUA, Fla. and TAMPA, Fla., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that management is scheduled to participate in three upcoming investor conferences:

Canaccord Genuity 20****th Annual MedTech, Diagnostics, Digital Health & Services Forum 
Participation: Fireside Chat and 1x1 investor meetings
Date/Time: Fireside Chat Wednesday, November 11, 2026, 10:00 AM ET

Jefferies Global Healthcare Conference in London
Participation: Fireside Chat and 1x1 investor meetings
Date/Time: Fireside Chat Tuesday, November 17, 2026, 8:30 AM ET

Piper Sandler 38****th Annual Healthcare Conference
Participation: Presentation and 1x1 investor meetings
Date/Time: Presentation Wednesday, December 2, 2026, 8:00 AM ET

Webcast events can be accessed live through the Investors page at www.axogeninc.com . For those unable to listen to the live broadcast, the replay will be archived for 90 days and available on the Investors page at www.axogeninc.com .

About Axogen

Axogen (Nasdaq: AXGN) is focused on the science, development and commercialization of technologies for peripheral nerve repair. With a mission to make nerve repair the expected standard of care, Axogen advances the field through research, education, and collaboration with surgeons and healthcare providers across a global network.

Axogen’s product portfolio includes Avance® (acellular nerve allograft-arwx), Avance® Nerve Graft, Axoguard Nerve Connector®, Axoguard Nerve Protector®, Axoguard HA+ Nerve Protector™, Axoguard Nerve Cap®, Avive+ Soft Tissue Matrix™, and NerveTape®.

Prompts

Axogen, Inc. (ticker AXGN), listed in United States.

Company History

Date Change Detail
Aug 2, 2011 Renamed LECTEC CORP /MN/ → AXOGEN, INC.

ETFs Holding Axogen, Inc.

ETF Weight in ETF Shares Market value As of
MMSC 0.70% 6,359 $ 352.161K Nov 16, 2026
FTKI 0.68% 3,129 $ 173.284K Nov 16, 2026
EHLS 0.51% 4,969 $ 275.183K Nov 17, 2026
SAWS 0.47% 877 $ 37.018K Jul 31, 2026
AFSM 0.43% 11,457 $ 634.489K Nov 16, 2026
SCDS 0.33% 549 $ 30.398K Nov 17, 2026
FSEG 0.28% 352 $ 16.259K Jun 30, 2026
ESSC 0.27% 2,271 $ 95.859K Jul 31, 2026
FESM 0.21% 265,129 $ 12.246M Jun 30, 2026
SEIS 0.18% 22,484 $ 1.039M Jun 30, 2026
VFMO 0.17% 65,187 $ 3.309M Aug 31, 2026
PSC 0.17% 83,461 $ 3.855M Jun 30, 2026
FSML 0.11% 3,095 $ 142.958K Jun 30, 2026
DFAS 0.04% 238,970 $ 13.239M Nov 12, 2026
MSSM 0.02% 3,186 $ 161.721K Aug 31, 2026
DFSU 0.01% 2,496 $ 138.278K Nov 12, 2026
DFUS 0.00% 15,763 $ 873.27K Nov 12, 2026
DCOR 0.00% 26,374 $ 1.461M Nov 12, 2026
DFAU 0.00% 7,359 $ 407.689K Nov 12, 2026
DFAC 0.00% 20,221 $ 1.12M Nov 12, 2026